Sensorion (STU:RFM) Valuation Rank


STU:RFM Sensorion SA STU:RFM
29 GF Score
Price €0.25
GF Value €0.43
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Sensorion Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sensorion Valuation Rank Related Terms

STU:RFM
29GF Score
Sensorion SA STU:RFM
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sensorion (STU:RFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sensorion stock appears to be undervalued. The current stock price of €0.25 is trading 41.7% below its estimated GF Value™ of €0.43. GuruFocus considers Sensorion to be Possible Value Trap.

Key valuation signals for STU:RFM:

  • Valuation Rank:
  • GF Value™: €0.43 vs. price of €0.25 (41.7% below fair value)
  • GF Score™: 29/100 with 1 warning sign

No single metric tells the full story. See the STU:RFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sensorion Business Description

Other Exchanges ALSEN:France
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
29GF Score

Get the complete analysis for STU:RFM

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.43
GF Value